Bolder BioTechnology
Manufacturing · Colorado, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2425 55th St Ste 210, Boulder, Colorado,...Phone Number
(303) 420-4420Website
www.bolderbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Bolder BioTechnology
Bolder BioTechnology is a leader in advanced protein engineering, focusing on the development of cost-effective and easy-to-use protein therapeutics aimed at improving patient lives. Their diversified product pipeline includes treatments for hematological and endocrine disorders, cancer, and infectious diseases, which they plan to commercialize independently and through strategic partnerships. Utilizing innovative technologies such as Site-Specific PEGylation and ImmunoFusion Protein technology, they enhance the efficacy and longevity of their protein products. The company also engages in BioDefense initiatives, supported by the U.S. government, to develop drugs for acute radiation exposure.Explore more
Bolder BioTechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bolder BioTechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Bolder BioTechnology recently announced quarterly report
Check out if Bolder BioTechnology is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Bolder BioTechnology
Bolder BioTechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Bolder BioTechnology launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Bolder BioTechnology has recently received funding, and reach out quickly before it becomes old news!
Click to see if Bolder BioTechnology had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Bolder BioTechnology has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Bolder BioTechnology
Compare insights from companies similar to Bolder BioTechnology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bolder BioTechnology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bolder BioTechnology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bolder BioTechnology.
Bolder BioTechnology News & Media
Bolder BioTechnology Announces Positive Preclinical Data for Use of BBT-032 to Inhibit Growth of the SARS-CoV-2 Virus
BOULDER, Colo., Aug. 25, 2020 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be...Bolder BioTechnology Receives NIH Grant to Advance Development of Novel Treatments for Acute Radiation Syndrome
BOULDER, Colo., July 18, 2019 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has been awarded a two year Small Business Innovation Research Grant totaling $593,507 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of...Bolder BioTechnology Announces FDA Orphan Drug Designation for BBT-059 for Acute Radiation Syndrome
BOULDER, Colo., June 12, 2019 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that its long-acting IL-11 analog, BBT-059, has received Orphan Drug designation from the Food and Drug Administration for treatment of Acute Radiation Syndrome (ARS). Orphan Drug designation is...Bolder BioTechnology to Present Preclinical Data for Three Research Programs at Acute Radiation Syndrome Meeting
BOULDER, Colo., Oct. 24, 2018 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, will give an oral presentation at the "A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS)" meeting being held October 25, 2018 at the National...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bolder BioTechnology
Sign Up For FreeTo access detailed company insights
Bolder BioTechnology is a leader in advanced protein engineering, focusing on the development of cost-effective and easy-to-use protein therapeutics aimed at improving patient lives. Their diversified product pipeline includes treatments for hematological and endocrine disorders, cancer, and infectious diseases, which they plan to commercialize ind... Read More
